PHARMAECONOMICANALYSISOF APPLICATION OF TWO NON-STEROID ANTIINFLAMMATORY DRUGS IN RHEUMATOLOGY
https://doi.org/10.14412/1995-4484-2002-754
Abstract
Movalis is a selective inhibitor of cyclooxigenase-2 and an effective NSAID. Its application enables us lo considerably reduce the risk of ihe development of side effects. Economic advantages of Movalis as compared with Voltaren arc formed by its lower price (considering exchange rate) and proved capability to reduce expenses on the treatment of complications.
References
1. <div><p>Насонова В.А. Новые данные о клинической эффективности н переносимости мелоксикама (мовалиса). Тер. архив., 1999, 71, II, 45-48.</p><p>Цветкова Е.С. Мовалис при остеоартрозе (данные российского исследования). Тер.архив., 1999, 71, И, 48-50.</p><p>Цветкова Е.С. Мовалис в терапии остеоартроза. Рсвма- тол„ 2001, 1, 67-71,</p><p>Экономическая оценка эффективности лекарственной терапии (фармакоэкономический анализ), иод ред.Воробье- ва П.А. М., Ньюдиамед, 2000, 80</p><p>Bevis P.J.R., Bird Н.А., Laplian G. An open study lo assess the safely and tolerability of meloxicam 15 mq in subjects with rheumatic disease and mild renal impairement. Br. I. Rheuma- lol., 1996, 35, suppel I. 56-60.</p><p>Garcia Rodriques L.A., Jick H. Rick of upper gastrointestinal bleeding and perforation associates wilh individual non - steroidal anti-inflammatory drugs. Lancet, 1994, 343, 769-772.</p><p>Giekcrsky К.Е., Huseby G., Rugstal И.Е. Epidemiology of NSAID - relate! gastrointestinal side effects. Scand. J. Gastro- enterd, 1989, 24, 3-8.</p><p>Hawkey C, Kalian A., Steinbruck K. et. al. Gastrointestinal tolerability of meloxicam compared lo diclofenac in osteoarthritis patients (“MELISSA”), Brit. J. Rheumatol., 1998, 37, 9, 937-945.</p><p>Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin like drugs. Nature (New Biol), 1971, 231,232235.</p><p>Vane J.R, Bolting J.M. Mechanism of action of anti-inflammatory drugs: an overview In. Selective COX -2 inhibitors. Pharmacology, clinical effects and therapeutical potentials. Ed. J.Vane, J.Botting. Kluwcr Academic Publisher, 1997, 1-17.</p><p>Janssen R.B., Capri S., Nuijten M.J.C. et al. Pharmacoecono- mic assessment meloxicam and diclofenae-SR treatment in osteoarthritis. Brit. 1 Med. Economics. 1997, 11, 9-22.</p></div><br />
Review
For citations:
Nassonova V.A., Vorobiev P.A., Tsvetkova E.S., Avksentieva M.V. PHARMAECONOMICANALYSISOF APPLICATION OF TWO NON-STEROID ANTIINFLAMMATORY DRUGS IN RHEUMATOLOGY. Rheumatology Science and Practice. 2002;40(1):63-68. (In Russ.) https://doi.org/10.14412/1995-4484-2002-754
Views:
596
Email this article 